Heikki Lanckriet, Pilar de la Huerta, Peter Llewellyn-Davis

Sygnis has announced changes to its management team and supervisory board. Former Co-CEO Heikki Lanckriet will become sole CEO of the company and will also retain his role as CSO. Additionally, supervisory board members Maria-Hesús Sabatés Mas and Franz Wilhelm Hopp will be ending their appointment terms and will not be up for re-election. Pilar de la Huerta and Peter Llewellyn-Davis will be nominated to replace them. De la Huerta will also resign from her position as member of the management board. Llewellyn-Davis currently serves as non-executive director and chairman of the audit committee of Shield Therapeutics. He previously served as CFO and chief business officer of MediGene.